Biparametric MRI in prostate cancer during active surveillance: is it safe?
Source : https://pubmed.ncbi.nlm.nih.gov/38656709/
Active surveillance (AS) is the preferred option for patients presenting with low-intermediate-risk prostate cancer. MRI now plays a crucial role for baseline assessment and ongoing monitoring of AS. The Prostate...
MRI is essential for monitoring low-intermediate-risk prostate cancer on active surveillance; biparametric MRI may suffice for stable patients, while multiparametric MRI and AI advancements enhance imaging quality and accuracy.
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
Source : https://pubmed.ncbi.nlm.nih.gov/39033689/
Prostate cancer (PCa) is the second most common cancer diagnosed in men. While radical prostatectomy and radiotherapy are often successful in treating localised disease, post-treatment recurrence is common. As the...
Targeting m6A epitranscriptomic modifications presents a promising strategy to enhance androgen signaling modulation and develop novel therapies for prostate cancer, addressing resistance and improving treatment outcomes for patients.
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39272956/
There is an unmet need to develop new treatments for metastatic prostate cancer. With the development of targeted radioligand therapies, bispecific T cell engagers, antibody-drug conjugates and chimeric antigen receptor...
The emergence of targeted therapies for metastatic prostate cancer, including radioligand treatments and CAR T therapies, offers promising avenues for improved outcomes through innovative targeting of tumor-associated antigens.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38644146/
Darolutamide + ADT + docetaxel led to deep and durable PSA responses in patients with high- or low-volume mHSPC. Achievement of undetectable PSA (<0.2 ng/ml) was correlated with better clinical...
Darolutamide combined with ADT and docetaxel significantly improved PSA responses, leading to better overall survival and delayed progression in metastatic hormone-sensitive prostate cancer patients, highlighting its clinical efficacy.
Metastatic hormone-naïve prostate cancer: a distinct biological entity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39048488/
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response...
A better understanding of mHNPC's clinical and biological features, along with biomarker-guided treatments and improved laboratory models, is essential to address unmet medical needs and enhance patient outcomes.